25 completed, 9 recruiting, 6 terminated, 5 withdrawn. 53 Phase 1, 19 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 53 | Completed 25, Recruiting 9, Terminated 6, Withdrawn 5, Unknown 4, Active not recruiting 3, Suspended 1 |
| Phase 2 | 19 | Completed 6, Terminated 4, Unknown 4, Withdrawn 4, Recruiting 1 |
Follow Chronic Myeloid Leukemia: new trials by email Literature Review of Chronic Myeloid Leukemia trials Research Report on Chronic Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic iNKT Cell Therapy (agenT-797) After SCT agenT-797 - Allogenic Stem Cell Transplantation, Myeloid Malignancies | Phase 1 | Recruiting | University of Wisconsin, Madison | 22 | 2026-11-01 | 2026-11-12 |
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Arizona | 180 | 2026-10-26 | 2026-10-29 |
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias CBX-250 - High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Recruiting | Crossbow Therapeutics, Inc. | 72 | 2025-07-16 | 2026-03-16 |
| TGRX-678 Pharmacokinetic Mass Balance [14C]TGRX-678 - Chronic Myeloid Leukemia | Phase 1 | Completed | Shenzhen TargetRx Co., Ltd. | 6 | 2025-07-07 | 2025-09-04 |
| TGRX-678 Phase I Oral Pharmacokinetic Study TGRX-678 - Chronic Myeloid Leukemia | Phase 1 | Completed | Shenzhen TargetRx Co., Ltd. | 76 | 2024-11-24 | 2025-05-16 |
| A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL) MK-4208 - Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase | Phase 1 / Phase 2 | Recruiting | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 330 | 2024-03-26 | 2026-10-15 |
| A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies Fludarabine + Total Marrow Irradiation - Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Naoyuki G. Saito, M.D., Ph.D. | 2023-10-01 | 2023-12-11 | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy | Phase 1 | Suspended | David Wald | 12 | 2022-09-09 | 2026-07-14 |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies MGD024 - Leukemia, Acute Myeloid, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | MacroGenics | 130 | 2022-07-13 | 2026-07-28 |
| A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia ELVN-001 - Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | Phase 1 | Recruiting | Enliven Therapeutics | 250 | 2022-05-22 | 2026-11-19 |
| KRT-232 and TKI Study in Chronic Myeloid Leukemia KRT-232, Dasatinib, Nilotinib - Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Kartos Therapeutics, Inc. | 109 | 2021-05-07 | 2022-03-21 |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3 - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Withdrawn | Medigene AG | 2020-07-02 | 2021-10-08 | |
| Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide EAGD T-cell infusion (Phase I), EAGD T-cell infusion (Expansion) - Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 | Recruiting | University of Kansas Medical Center | 38 | 2020-01-31 | 2026-03-25 |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab - Leukemia, Myeloid, Chronic, Myeloid Leukemia | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 242 | 2020-01-09 | 2025-11-05 |
| Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Orca-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Active not recruiting | Orca Biosystems, Inc. | 155 | 2019-11-21 | 2026-08-14 |
| Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia Chronic Myeloid Leukemia + NK cell - Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Hospital de Clinicas de Porto Alegre | 5 | 2019-03-01 | 2019-03-12 |
| Selumetinib and Azacitidine in High Risk Chronic Blood Cancers Azacitidine, Selumetinib - Chronic Myeloid Leukemia, Myelofibroses | Phase 1 | Recruiting | University of Chicago | 18 | 2018-09-04 | 2025-12-29 |
| IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT Fludarabine, Total Marrow Irradiation (TMI) - Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 | Terminated | Naoyuki G. Saito, M.D., Ph.D. | 6 | 2018-08-29 | 2022-03-09 |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Natural Killer (NK) Cells, ALT803 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Completed | Brenda Cooper, MD | 14 | 2018-05-22 | 2023-02-21 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
Showing 20 of 53. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (53) · Leukemia, Myeloid, Acute (23) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (23) · Myelodysplastic Syndromes (22) · Lymphoma, Non-Hodgkin (10) · Multiple Myeloma (8) · Primary Myelofibrosis (7) · Hodgkin Disease (6) · Hematologic Neoplasms (4) · Leukemia (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia, Myeloid, Chronic-Phase (4) · Blastic Plasmacytoid Dendritic Cell Neoplasm (3) · Leukemia, Myelomonocytic, Chronic (3) · Blast Crisis (2)
Bone Marrow Diseases (53) · Chronic Disease (53) · Disease Attributes (53) · Hematologic Diseases (53) · Hemic and Lymphatic Diseases (53) · Neoplasms (53) · Neoplasms by Histologic Type (53) · Pathologic Processes (53) · Pathological Conditions, Signs and Symptoms (53) · Leukemia, Myeloid (51) · Myeloproliferative Disorders (51) · Leukemia (49) · Immune System Diseases (26) · Immunoproliferative Disorders (26) · Lymphatic Diseases (26)
Imatinib Mesylate (5) · nilotinib (5) · fludarabine (3) · fludarabine phosphate (3) · Azacitidine (2) · Busulfan (2) · Cyclophosphamide (2) · Cytarabine (2) · Dasatinib (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · 1-cyclopropyl-3-(3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl)urea (1) · 4-fluorobenzoyl-TN-14003 (1) · ALT-803 (1) · AZD 6244 (1)
Novartis Pharmaceuticals (4) · M.D. Anderson Cancer Center (2) · Naoyuki G. Saito, M.D., Ph.D. (2) · Shenzhen TargetRx Co., Ltd. (2) · American Regent, Inc. (1) · Ascentage Pharma Group Inc. (1) · Astex Pharmaceuticals, Inc. (1) · Baylor College of Medicine (1) · Brenda Cooper, MD (1) · Bristol-Myers Squibb (1) · Case Comprehensive Cancer Center (1) · Cellerant Therapeutics (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chong Kun Dang Pharmaceutical (1) · Crossbow Therapeutics, Inc. (1)
United States (33) · Germany (9) · France (8) · South Korea (6) · Italy (5) · Canada (4) · Israel (4) · Spain (4) · United Kingdom (4) · Australia (3) · China (3) · Netherlands (3) · Belgium (2) · Poland (2) · Russia (2)
Jorge Cortes, MD (3) · Andreas Hochhaus, Prof. Dr. med. (1) · Anna Turkina, Professor (1) · Arnon Nagler, MD (1) · Ashok Srinivasan, MD (1) · B. Douglas Smith, MD (1) · Benjamin Tomlinson, MD (1) · Briggs Morrison, MD (1) · Dale Bixby, M.D., Ph.D. (1) · David Snyder, M.D. (1) · David Wald, MD, PhD (1) · Ehab Atallah, MD (1)
PMID 16990776, PMID 21145590, PMID 21540460, PMID 22047558, PMID 22825216, PMID 22987312, PMID 24060561, PMID 24355079, PMID 24753538, PMID 25394714, PMID 26072403, PMID 26639404, PMID 27927766, PMID 33635333, PMID 35982483, PMID 38467031, PMID 38683966, PMID 39570620, PMID 40298994
2009 (1), 2023 (1)